Sernova Responds to Dissident Shareholders’ Misleading Statements and Provides Corporate Updates
April 06, 2023 07:00 ET
|
Sernova Corp.
The dissident director nominees declined to follow proper protocol to participate in Sernova’s board renewal process and instead are imposing themselves on the Company through a costly and disruptive...
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023
March 22, 2023 07:00 ET
|
Sernova Corp.
LONDON, Ontario, March 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that an...
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
March 14, 2023 07:00 ET
|
Sernova Corp.
LONDON, Ontario, March 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract...
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
March 08, 2023 07:00 ET
|
Sernova Corp.
Third patient now implanted with higher capacity, 10-chamber Cell PouchCompany anticipates first interim data from second cohort in Q4 2023 LONDON, Ontario, March 08, 2023 (GLOBE NEWSWIRE) --...
Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
March 02, 2023 07:00 ET
|
Sernova Corp.
LONDON, Ontario, March 02, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be...
Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy
January 30, 2023 07:30 ET
|
Sernova Corp.
Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid glandSernova has engaged...
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
January 10, 2023 07:00 ET
|
Sernova Corp.
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type...
Sernova Corp. Announces CEO Succession Plan and Expanded Management Team
December 06, 2022 07:00 ET
|
Sernova Corp.
LONDON, Ontario, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as...
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
November 17, 2022 07:30 ET
|
Sernova Corp.
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into the enhanced 10-channel Cell...
Sernova to Participate in the Stifel Healthcare Conference
November 04, 2022 07:30 ET
|
Sernova Corp.
LONDON, Ontario, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be...